Article Text

Download PDFPDF

PR016/#541  Detection of human papillomvirus circulating tumor DNA (CTDNA) as a novel approach to cervical cancer screening and monitoring
  1. Erica Mandato1,
  2. Tadhg Ferrier1,
  3. Simane Warsame1,
  4. Hila Tabrizian1,
  5. Fady Mansour2,
  6. Basile Tessier-Cloutier3,
  7. Xing Zeng4,
  8. Julia Burnier5 and
  9. Shuk On Annie Leung6
  1. 1Research Institute of the McGill University Health Centre (RI-MUHC), Pathology, Montreal, Canada
  2. 2MUHC, Gynecology, Minimally Invasive Gynecology and Obstetrics, Montreal, Canada
  3. 3Cancer Research Program RI-MUHC, Pathology, Montreal, Canada
  4. 4MUHC, Gynecologic Oncology, Montreal, Canada
  5. 5Cancer Research Program RI-MUHC, Oncology, Montreal, Canada
  6. 6Cancer Research Program RI-MUHC, Gynecologic Oncology, Montreal, Canada


Introduction Cervical cancer is the 4th most common cancer in women worldwide. Majority of cases are caused by human papillomavirus (HPV) infection and early detection is possible with cytology and/or HPV-DNA. However, cytology has a low sensitivity, and the HPV-DNA test has a low specificity in distinguishing transient from clinically significant HPV infections. Furthermore, there are limited non-invasive options for surveillance post-treatment. Liquid biopsy is a non-invasive approach aimed at addressing these limitations. This study aimed to demonstrate that HPV circulating tumour (ct)DNA levels in blood, urine, and vaginal swabs correlate with extent of disease.

Methods Using ddPCR, primers were designed to target the viral E7 oncogene sequence from high-risk HPV subtypes (hrHPV 16, 18 and 33). Samples were collected from patients with cervical dysplasia ranging from low to high grade (pre-cancer group, n=22) and patients with a new cervical cancer diagnosis (cancer group, n=23).

Results HPV ctDNA was detected in more cancer patients (13/23, 56.5%) than pre-cancer patients (1/22, 4.5%). Among the ctDNA-positive patients, the concentration was higher in the urine and vaginal swabs compared to blood. Furthermore, samples collected from cancer patients at multiple timepoints (n=7) showed that ctDNA decreased post-treatment.

Conclusion/Implications HPV ctDNA levels correlated to the extent of disease and was detectable in different liquid biopsy samples. Liquid biopsy has the potential to serve as a non-invasive complementary method to existing techniques both in screening and monitoring of cervical pre-cancer and cancer. Future work will explore other hrHPV subtypes and the performance of individual analytes.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.